Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Express Scripts
McKesson
Merck
Dow

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TOPOTECAN

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Topotecan

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00001333 Phase I Study of Intrathecal Topotecan Completed National Cancer Institute (NCI) Phase 1 1993-02-01 The purpose of this study is to determine the qualitative and quantitative toxicity of intrathecal topotecan, a topoisomerase I inhibitor, in patients with meningeal malignancies refractory to conventional therapy (radiation therapy and chemotherapy).
NCT00002395 Safety and Effectiveness of Topotecan HCl to Treat HIV-Infected Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy (PML) Completed SmithKline Beecham Phase 2 1969-12-31 The purpose of this study is to see if it is safe and effective to give topotecan through a vein to treat HIV-infected patients with PML, an opportunistic (AIDS-related) infection caused by a virus that infects brain tissue and causes damage to the brain and the spinal cord. Topotecan fights HIV and the JC virus (the virus that causes PML) in laboratory experiments.
NCT00002515 Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer Completed Memorial Sloan Kettering Cancer Center Phase 2 1992-10-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bone marrow transplantation may allow doctors to give higher doses of chemotherapy and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy with thiotepa, carboplatin, and topotecan followed by bone marrow transplantation in treating patients who have metastatic or progressive rare cancer.
NCT00002537 Radiation Therapy Plus Topotecan in Treating Patients With Non-small Cell Lung Cancer Completed National Cancer Institute (NCI) Phase 1 1993-09-01 Phase I trial to study the effectiveness of radiation therapy plus topotecan in treating patients who have non-small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy and radiation therapy may kill more tumor cells.
NCT00002587 Paclitaxel Plus Topotecan in Treating Patients With Solid Tumors Completed National Cancer Institute (NCI) Phase 1 1994-09-01 Phase I trial to study the effectiveness of paclitaxel plus topotecan in treating patients who have solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
NCT00002588 Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia Completed National Cancer Institute (NCI) Phase 1 1994-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of topotecan and etoposide in treating patients who have recurrent or refractory leukemia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Topotecan

Condition Name

Condition Name for Topotecan
Intervention Trials
Ovarian Cancer 70
Small Cell Lung Cancer 32
Neuroblastoma 30
Lung Cancer 28
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Topotecan
Intervention Trials
Lung Neoplasms 80
Small Cell Lung Carcinoma 78
Ovarian Neoplasms 74
Neuroblastoma 38
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Topotecan

Trials by Country

Trials by Country for Topotecan
Location Trials
Canada 129
Germany 48
Australia 39
Italy 35
United Kingdom 33
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Topotecan
Location Trials
California 74
New York 72
Ohio 71
Florida 68
Texas 68
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Topotecan

Clinical Trial Phase

Clinical Trial Phase for Topotecan
Clinical Trial Phase Trials
Phase 4 1
Phase 3 46
Phase 2/Phase 3 3
[disabled in preview] 298
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Topotecan
Clinical Trial Phase Trials
Completed 206
Recruiting 51
Terminated 36
[disabled in preview] 64
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Topotecan

Sponsor Name

Sponsor Name for Topotecan
Sponsor Trials
National Cancer Institute (NCI) 129
GlaxoSmithKline 57
Children's Oncology Group 14
[disabled in preview] 36
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Topotecan
Sponsor Trials
Other 341
Industry 165
NIH 134
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Johnson and Johnson
Moodys
Colorcon
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.